Mepolizumab: 240563, Anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563

Drugs in R and D

Volumn 9, Issue 2, 2008, Pages 125-130

[No Author Info available]

Author keywords

Asthma; Eosinophilia; Interleukin 5 antagonists, therapeutic use; Mepolizumab, therapeutic use; Nasal polyps; Oesophagitis; Research and development

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; INTERLEUKIN 5 ANTIBODY; MEPOLIZUMAB; ORPHAN DRUG; PLACEBO; PREDNISONE;

ABSENCE OF SIDE EFFECTS; ALLERGIC ASTHMA; ASTHMA; ATOPIC DERMATITIS; ATOPY; BRONCHUS HYPERREACTIVITY; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHIL COUNT; EOSINOPHILIA; EOSINOPHILIC ESOPHAGITIS; FORCED EXPIRATORY VOLUME; HUMAN; HYPEREOSINOPHILIC SYNDROME; NOSE POLYP; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; REVIEW; VASCULITIS; WELLS SYNDROME;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HEMATOLOGIC DISEASES; HUMANS; INTERLEUKIN-5; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 39849098967     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200809020-00006     Document Type: Review

References (12)

1. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. American Journal of Respiratory and Critical Care Medicine 176: 1062-1071, No. 11, 1 Dec 2007
2. Cincinnati Childrens Hospital Medical Center. Cincinnati Children's Researchers Publish Positive Findings from Clinical Study of Investigational Treatment for Debilitating Allergic Disorder. Media Release: 20 Dec 2006. Available from URL: http://www.prnewswire.com
3. Zia-Amirhosseini P, Walls C, Patel B. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in mild asthmatics. Clinical Pharmacology and Therapeutics 65: 147, Feb 1999
4. Straumann A, Conus S, Kita H, et al. Mepolizumab, a humanized monoclonal antibody to IL-5, for severe eosinophilic esophagitis in adults: a randomized, placebo-controlled double-blind trial. Gut 56 (Suppl. 3): 7, Oct 2007
5. Flood-Page P, Phipps S, Menzies-Gow A, et al. Effect of intravenous administration of an anti-IL-5 mAb (mepolizumab) on allergen-induced tissue eosinophilia, the late-phase allergic reaction and the expression of a marker of repair/remodeling in human atopic subjects. Journal of Allergy and Clinical Immunology 111 (Suppl.): 261 (plus poster), Feb 2003
6. Menzies-Gow A, Flood-Page P, Compton C, et al. A double blind, placebo-controlled, parallel group study to assess the effect of mepolizumab (humanised monoclonal anti-IL-5 antibody) on bone marrow and peripheral blood eosinophils and eosinophil progenitors in atopic asthmatics. American Journal of Respiratory and Critical Care Medicine 165: B50, Part 2, Apr 2002
7. Phipps S, Flood-Page P, Menzies-Gow A, et al. Anti-IL-5 (mepolizumab) reduces the expression of tenascin, procollagen III and lumican in the reticular basement membrane of human atopic asthmatics. Journal of Allergy and Clinical Immunology 111 (Suppl.): 278 (plus oral presentation), Feb 2003
8. Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. American Journal of Respiratory and Critical Care Medicine 167: 199-204, 15 Jan 2003
9. Weller PF, Gleich GJ, Busse WW, et al. Effects of mepolizumab, an anti-interleukin-5 monoclonal antibody, on blood eosinophil counts in patients with hypereosinophilic syndrome. Journal of Allergy and Clinical Immunology 119 (Suppl.): 209, No. 1, Jan 2007
10. Plötz S-G, Simon H-W, Darsow U, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. New England Journal of Medicine 349: 2334-2339, No. 24, 11 Dec 2003
11. Garrett JK, Jameson SC, Thomson B, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. Journal of Allergy and Clinical Immunology 113: 115-119, No. 1, Jan 2004
12. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356: 2144-2148, 23-30 Dec 2000